MetaXplore GI Plus vs GI-Map: How Gut Health Testing Is Evolving in Australia

Author: Rohan Smith | Functional Medicine Practitioner | Adelaide, SA

Quick Answer. Why MetaXplore GI Plus Represents a Shift in Microbiome Assessment

Gut health testing has evolved beyond simply identifying and eliminating individual “problem” microbes. While targeted stool tests such as GI-Map have been valuable for detecting specific pathogens, advances in microbiome science now allow for a broader, systems-level view of the gut. MetaXplore GI Plus, developed by Microba, uses shotgun metagenomic sequencing to characterise microbial diversity, functional capacity, and overall microbial balance, rather than focusing only on predefined organisms.

This shift does not mean earlier tests were ineffective. Instead, it reflects a change in scientific understanding: long-term gut health appears to be associated not only with the absence of pathogens, but with gut microbiome diversity, resilience, and metabolic function. Importantly, microbiome testing is not required for everyone, and results must always be interpreted in clinical context. No stool test alone can diagnose disease or predict outcomes.

Clinical Context: Experience With Pathogen-Focused Testing

For many years, GI-Map testing has been used clinically to help identify bacterial and parasitic organisms associated with digestive symptoms. In appropriate cases, this approach can support targeted interventions, and many individuals experience meaningful symptom improvement.

Over time, however, it has become increasingly clear that gut health is best understood as a complex biological system rather than a simple “good versus bad bacteria” model. In some cases, removing organisms without addressing broader microbial balance may not support long-term resilience, and a subset of individuals experience recurrent or evolving symptoms despite apparent pathogen clearance.

The Paradigm Shift: From Elimination to Ecosystem Support

Current microbiome research suggests that microbial diversity and functional capacity are associated with gut stability and broader health outcomes (1–4).

• Microbial diversity refers to the number and balance of different microbial species present.
• Functional capacity describes what those microbes are capable of doing—such as producing short-chain fatty acids (SCFAs), supporting gut barrier integrity, and interacting with immune signalling pathways.

This does not imply that pathogens are irrelevant. Acute infections and clinically significant overgrowths still require appropriate attention. The shift is toward addressing these factors while also supporting microbial recovery, rather than focusing exclusively on eradication.

Understanding the Technology

qPCR (GI-Map)

Quantitative polymerase chain reaction (qPCR) is a molecular method that detects and quantifies predefined microbial targets. It is highly sensitive and specific, but limited to organisms included in the test panel (5).

Shotgun Metagenomic Sequencing (MetaXplore GI Plus)

Shotgun metagenomics sequences all microbial DNA present in a stool sample. This enables identification of bacteria, archaea, fungi, and other microorganisms without relying on a predetermined checklist (6–8).

This approach provides insight into:

• Overall microbial diversity
• Relative abundance patterns
• Genetic pathways related to metabolism and gut function

As with all advanced testing, results require careful interpretation and do not establish causation on their own.

Why Australian Reference Data Matters

Microbiome composition varies based on diet, geography, environment, and lifestyle (9–11). MetaXplore GI Plus compares results against healthy Australian reference cohorts, which may improve contextual relevance for Australian patients. This reflects population specificity rather than superiority.

From Pathogen-Focused to Function-Informed Testing

Limitations of a Pathogen-Only Model

Pathogen-focused testing can be effective, but some individuals experience:

• Symptom recurrence after initial improvement
• Shifts in microbial balance following treatment
• Persistent dysbiosis despite pathogen clearance

These patterns highlight the importance of looking beyond individual organisms alone.

Functional and System-Level Insights

MetaXplore GI Plus reports on:

• Microbial diversity indices
• Functional gene pathways
• Gastrointestinal health markers, including calprotectin, lactoferrin, pancreatic elastase, and secretory IgA

Markers such as zonulin remain clinically debated and should be interpreted cautiously, as stool and serum measurements do not consistently reflect intestinal permeability (12–14).

What This Means for Treatment Planning

Microbiome test results are informational rather than diagnostic. When clinically appropriate, they may help inform strategies such as:

• Targeted prebiotic and dietary interventions
• Selective, evidence-based probiotic use
• Support for digestive and immune function

Individual responses vary, and improvements cannot be guaranteed.

Who May Consider Comprehensive Microbiome Testing

Comprehensive microbiome testing may be considered for individuals:

• With persistent digestive symptoms despite standard care
• Recovering from antibiotic exposure or prolonged stress
• Exploring gut health in the context of chronic or unexplained symptoms

For those who are symptom-free and clinically stable, repeat or advanced testing may not be necessary.

The Bottom Line

The evolution of gut health testing reflects advances in microbiome science and a broader understanding of gastrointestinal health. Gut function appears to be influenced not only by the absence of pathogens, but by microbial diversity, functional capacity, and overall resilience. No single test provides all the answers, but broader microbiome assessment may offer additional clinical context when used judiciously.

Learn more about comprehensive microbiome testing and how results are interpreted in a clinical setting.

References

1. Lozupone CA, Stombaugh JI, Gordon JI, Jansson JK, Knight R. Diversity, stability and resilience of the human gut microbiota. Nature. 2012.
2. Sonnenburg JL, Bäckhed F. Diet–microbiota interactions as moderators of human metabolism. Nature. 2016.
3. Valdes AM, Walter J, Segal E, Spector TD. Role of the gut microbiota in nutrition and health. BMJ. 2018.
4. Lloyd-Price J, Abu-Ali G, Huttenhower C. The healthy human microbiome. Nature. 2019.
5. Verweij JJ, Stensvold CR. Molecular testing for clinical diagnosis and epidemiological investigations of intestinal parasitic infections. Clinical Microbiology Reviews. 2014.
6. Quince C, Walker AW, Simpson JT, Loman NJ, Segata N. Shotgun metagenomics, from sampling to analysis. Nature Biotechnology. 2017.
7. Franzosa EA, McIver LJ, Rahnavard G, et al. Species-level functional profiling of metagenomes and metatranscriptomes. Nature Methods. 2018.
8. Sharpton TJ. An introduction to the analysis of shotgun metagenomic data. Briefings in Bioinformatics. 2014.
9. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. PNAS. 2010.
10. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012.
11. Rothschild D, Weissbrod O, Barkan E, et al. Environment dominates over host genetics in shaping the human gut microbiota. Nature. 2018.
12. Fasano A. Zonulin, regulation of tight junctions, and autoimmune diseases. Physiological Reviews. 2011.
13. Scheffler L, Crane A, Heyne H, et al. Widely used permeability markers fail to reflect intestinal barrier function in vivo. Gut. 2018.
14. McMahon G, Sabounchi S, Higgins S, et al. Biomarkers of intestinal permeability: Clinical relevance and limitations. Clinical and Experimental Gastroenterology. 2020.